To evaluate the effect of ofatumumab on B-cell depletion and efficacy outcomes in the subgroup of patients from ASCLEPIOS I/II trials defined by their baseline body mass index (BMI).
No takes yet. Share an insight, caveat, or question.
Cross et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: